A new systematic review published in the International Journal of Radiation Oncology Biology Physics examines the role of brachytherapy for gynecologic reirradiation, an important but highly complex salvage option for patients with locoregionally recurrent gynecologic cancers after prior radiation.
The article, “Reporting and Outcomes of Brachytherapy for Gynecologic Re-irradiation: A Systematic Review,” focuses not only on clinical outcomes, but also on how these studies are reported. This is especially important because reirradiation decisions are highly individualized and depend on prior treatment, recurrence site, tumor size, time since initial radiation, cumulative dose, organs at risk, and patient fitness.
Why This Topic Matters
Recurrent gynecologic cancer in a previously irradiated pelvis is one of the most difficult scenarios in radiation oncology.
For selected patients without distant disease, curative salvage treatment may still be possible. Options are limited and often include pelvic exenteration or reirradiation. Brachytherapy is particularly attractive because it can deliver a high dose directly to the recurrent tumor while limiting exposure to surrounding tissues through steep dose fall-off.
This makes image-guided adaptive brachytherapy a theoretically strong approach for central or paracentral pelvic recurrences. However, the risk of severe late toxicity remains substantial, and the evidence base is still limited.
What the Review Included
The authors performed a systematic literature search according to PRISMA guidance, covering publications from January 1990 to September 2025.
In total, 50 original publications were included, representing 1,978 patients. Among them, 1,408 patients underwent reirradiation. Most studies were retrospective, and the average sample size was small, with a mean of 28.2 patients.
The review also analyzed 16 more recent studies published between 2019 and September 2025, which predominantly used modern image-guided brachytherapy techniques.
Key Outcomes
Modern gynecologic reirradiation using brachytherapy showed encouraging outcomes in selected patients.
Across recent studies, local control ranged from 35% to 87% at 1 year and from 26% to 59% at 5 years. Overall survival ranged from 52% to 83% at 1 year and from 34% to 54% at 5 years.
However, toxicity remains an important concern. Grade 3 to 4 late toxicity ranged from 0% to 33% across recent series. Reported complications included gastrointestinal, genitourinary, vaginal toxicity, fistula formation, ulceration, bleeding, and bowel complications.
The review also identified several factors that may influence outcomes. Better results were suggested in patients with smaller recurrences, longer intervals since prior radiotherapy, complete response after reirradiation, and higher brachytherapy dose to the target. Higher toxicity risk was associated with larger tumors, higher cumulative EQD2, shorter interval from prior radiation, and use of bevacizumab at any point during treatment.
The Reporting Problem
One of the most important messages of this review is that the literature is difficult to compare because reporting is inconsistent.
Across the 50 included studies, key details were often missing. Only 58% reported the interval from prior radiation to reirradiation. Treatment intent was reported in only 30% of studies. Target aims were reported in 38%, and organs-at-risk constraints in only 26%.
Although local control and toxicity were commonly reported, follow-up methods and toxicity scoring systems were frequently incomplete. None of the included studies reported post-reirradiation quality of life.
This is a major gap because reirradiation is not only about tumor control. In this setting, functional outcomes, late toxicity, fistula risk, symptom burden, and quality of life are central to treatment decisions.
What the Figures Show
The PRISMA diagram shows that 50 studies were included, with 38 identified through database search and 12 through citation screening.
The publication trend figure shows increasing interest in gynecologic reirradiation with brachytherapy over time, particularly from 2015 onward, but also highlights that many recent publications are reviews rather than large prospective datasets.
The heterogeneity figure is especially important. It shows wide variation in tumor types, use of external beam radiotherapy, chemotherapy timing, brachytherapy techniques, dose rates, isotopes, imaging methods, and target-dose specification. This explains why drawing firm conclusions across studies remains challenging.
The reporting figure summarizes the central issue of the paper: many essential clinical, dosimetric, and outcome parameters are still underreported.
Who May Be an Ideal Candidate
Based on the available evidence and expert interpretation, the authors describe a potential ideal candidate for gynecologic reirradiation using brachytherapy.
This would generally be a patient in good condition, with isolated central or paracentral pelvic recurrence, tumor size less than 4 to 5 cm or less than 30 cm³, and an interval of more than 12 to 24 months since the first course of radiation.
The authors also emphasize that these patients should be evaluated in a multidisciplinary tumor board and referred to specialized centers with strong expertise in image-guided adaptive brachytherapy.
Clinical Takeaway
Gynecologic reirradiation using brachytherapy is a reasonable salvage option for carefully selected patients with recurrent gynecologic cancers after prior radiation.
Modern image-guided brachytherapy has improved the precision of treatment and may offer meaningful local control. However, the risk of severe late toxicity remains real, and current evidence is limited by retrospective designs, small sample sizes, heterogeneous treatment techniques, and incomplete reporting.
The main message is clear: the field needs standardized terminology, better dose-summation methods, prospective multi-institutional registries, and more consistent reporting of toxicity, organs-at-risk constraints, treatment intent, patient selection, and quality of life.
For now, GRIB should be considered a specialized, individualized salvage approach requiring expert brachytherapy teams, careful patient selection, and shared decision-making.
Read full article.